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ABSTRACT
Introduction: Respiratory tract infections (RTIs)
account for about 60% of antibiotics prescribed in
primary care. This study aims to test the effectiveness,
in a cluster randomised controlled trial, of electronically
delivered, multicomponent interventions to reduce
unnecessary antibiotic prescribing when patients
consult for RTIs in primary care. The research will
specifically evaluate the effectiveness of feeding back
electronic health records (EHRs) data to general
practices.
Methods and analysis: 2-arm cluster randomised
trial using the EHRs of the Clinical Practice Research
Datalink (CPRD). General practices in England, Scotland,
Wales and Northern Ireland are being recruited and the
general population of all ages represents the target
population. Control trial arm practices will continue with
usual care. Practices in the intervention arm will receive
complex multicomponent interventions, delivered
remotely to information systems, including (1) feedback
of each practice’s antibiotic prescribing through monthly
antibiotic prescribing reports estimated from CPRD data;
(2) delivery of educational and decision support tools; (3)
a webinar to explain and promote effective usage of the
intervention. The intervention will continue for
12 months. Outcomes will be evaluated from CPRD
EHRs. The primary outcome will be the number of
antibiotic prescriptions for RTIs per 1000 patient years.
Secondary outcomes will be: the RTI consultation rate;
the proportion of consultations for RTI with an antibiotic
prescribed; subgroups of age; different categories of RTI
and quartiles of intervention usage. There will be more
than 80% power to detect an absolute reduction in
antibiotic prescription for RTI of 12 per 1000 registered
patient years. Total healthcare usage will be estimated
from CPRD data and compared between trial arms.
Ethics and dissemination: Trial protocol was approved
by the National Research Ethics Service Committee
(14/LO/1730). The pragmatic design of the trial will
enable subsequent translation of effective interventions
at scale in order to achieve population impact.
Trial registration number: ISRCTN95232781;
Pre-results.
BACKGROUND
Respiratory tract infections (RTIs), including
cough, acute bronchitis, common colds,
Strengths and limitations of this study
▪ This intervention will use electronic health records
as means to inform, deliver and evaluate the
effectiveness of a cluster trial to support antibiotic
prescribing. This intervention, if effective, could
be easily translated into routine practice settings.
▪ If successful, this study could help reduce anti-
biotic resistance—a growing problem that trans-
cends national boundaries
▪ Although behavioural theory and qualitative
research were used to enhance the effectiveness
of intervention design, it was not possible to
include all identified factors without creating an
intervention which would be too complex and
difficult to use.
▪ It is possible that the intervention will have a
smaller effect than expected as problems with
implementation might be encountered (eg, low
adherence to electronic prompts). This will be
examined during process evaluation.
▪ Initiatives to influence antibiotic prescribing both
locally and nationally could influence the results
of the current trial if these external influences
contributed to optimal performance improvement
across both trial arms.
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otitis media, sinusitis and sore throat (including laryngi-
tis, pharyngitis and tonsillitis) are among most common
presentations in primary care.1 2 A majority of these
infections are self-limiting3–5 and the UK guidance
recommends no antibiotic strategy or a delayed anti-
biotic prescription for otherwise healthy adults,2 but
∼50% of patients who present with a RTI are prescribed
an antibiotic.6 This overprescribing has negative conse-
quences for the patients and for the wider public.
Antibiotics can be associated with a number of possible
unpleasant side effects for patients such as thrush or
diarrhoea, and occasionally they can cause severe aller-
gic reactions.7 Inappropriate prescribing increases the
perception that antibiotics are an effective treatment for
self-limiting infections increasing the likelihood of con-
sultation for a similar condition in the future as patients
believe that antibiotics are effective in these
circumstances.8
Overusage of antibiotics in primary care also contri-
butes to the emergence of antimicrobial drug resistance,
increasing the risk of infections that may be very difﬁcult
to treat in the local community as well as for individual
patients. Research evidence suggests that patients pre-
scribed antibiotics for respiratory or urinary tract infec-
tion in primary care might develop bacterial resistance
for up to 12 months.9 Recent analyses of data from
Clinical Practice Research Datalink (CPRD) suggest an
overall prescribing proportion of between 50% and 60%
for RTIs, with 70% of episodes of otitis media and 90%
of episodes of sinusitis resulting in antibiotic prescrip-
tion.1 6 Such rates of prescribing suggest that nearly all
general practices are currently prescribing antibiotics at
rates that are ‘way off the mark’10 in the context of good
practice recommendations, which advise that most RTIs
can be managed without the prescription of antibiotics.2
Although there are no available guidelines on safe level
of antibiotic prescribing for RTIs, the results of an ana-
lysis of Dutch primary healthcare records demonstrate a
signiﬁcantly lower prescribing rate compared with the
UK, with ∼22.5% patients consulting with a RTI episode,
being issued a prescription.11 Since majority of antibiotic
prescribing takes place in primary care, the manage-
ment of these infections offers an opportunity to make a
major impact on unnecessary antibiotic prescribing. The
Department of Health as a part of the UK Antimicrobial
Resistance Strategy identiﬁed education and training as
a key measure to reduce inappropriate and unnecessary
antibiotic prescribing.12
A number of previous randomised controlled trials
have tested strategies to reduce unnecessary antibiotic
prescribing. A review of such interventions conducted
up to 2007 which included 30 trials, found a median
reduction in the proportion of participants receiving
antibiotics of 9.7% (IQR 6.6–13.7%).13 Most studies
employed educational activities aimed at clinicians or
patients, or audit of antibiotic prescribing with feedback
of results, or a combination of these interventions.
Recent trials which have used similar intervention
strategies, but have more frequently used electronic
media to deliver advice on appropriate prescribing,14 15
have demonstrated similar reductions in antibiotic
usage, with reduction in antibiotic prescribing of up to
15% in the GRACE trial. However, previous trials
required resource-intensive interventions, and these
intervention techniques have not yet been translated on
a wide and sustainable scale into routine healthcare. For
example, the trial by Gonzales et al16 required clinicians
to participate in a half-day training session, with triage
nurses providing patients with education leaﬂets to read
before their consultation. The challenge now is to take
the components of intervention that have been shown
to be effective and to ﬁnd methods to deploy these efﬁ-
ciently into routine practice settings.
Our group recently completed a trial (electronic
Cluster Randomised Trial, eCRT) in which 104 general
practices in England and Scotland, which contributed
electronic health records (EHRs) to a national primary
care database the CPRD, were randomised.17
Intervention practices had decision support tools deliv-
ered remotely using the practice systems that are
employed in delivering routine primary care. These
decision support tools on antibiotic prescribing
appeared on intervention family practitioners’ screen
during consultations for speciﬁc RTIs. This simple inter-
vention showed a near two percentage point reduction
in antibiotic prescribing.18 This trial also demonstrated
that EHRs can be used successfully as a means to
inform, deliver and evaluate the effectiveness of an inter-
vention to support reduced antibiotic prescribing.
Process evaluation undertaken as a part of the eCRT
study suggested that although the intervention resulted
in a signiﬁcant reduction of antibiotic prescriptions
among intervention practices, the intervention tools
have been underused by many participating general
practitioners (GPs). For example, some GPs were not
aware of the implementation of the system into their
practice.16 These ﬁndings taken together with evidence
from the systematic review, recent trials and systematic
reviews of the wider implementation science litera-
ture,19 20 identify ways to increase engagement in the
intervention and increase effect size.21 This research is
at a later stage of translation than previous randomised
trials evaluating strategies to reduce antibiotic prescrib-
ing. In order to overcome the block in the translational
pathway, there is now a need to develop and evaluate
more effective complex multicomponent interventions
that can be implemented and delivered remotely. The
research will focus on interventions that can be readily
scaled up, through remote delivery using electronic
media, to large samples of unselected practices.
AIMS
The primary objective of the proposed study is to evalu-
ate whether a complex multicomponent, but low-cost
intervention to inﬂuence GPs’ prescribing of antibiotics
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when patients consult with RTIs, delivered electronically
at the level of general practice, reduces antibiotic pre-
scribing rates in primary care.
METHODS/DESIGN
This trial is a two-arm cluster randomised trial with
general practices as the unit of allocation. Consenting
GP practices who meet eligibility criteria (as deﬁned in
Study setting and target population section) are allo-
cated to intervention and control trial arms by minimisa-
tion. Control trial arm practices will continue with usual
clinical care. Usual care has been chosen as the control
groups since current trail aims to test if current interven-
tion is better than or at least equivalent to current clin-
ical practice. An internal pilot will be conducted to
demonstrate the feasibility and acceptability of the inter-
vention in 20 general practices. The components of the
intervention will be delivered to practices allocated to
the intervention trial arm. In the pilot phase, intermedi-
ate outcome measures will include (1) successful installa-
tion of the decision support tools at intervention
practices; (2) successful delivery of practice prescribing
reports and webinars to intervention trial arm practices;
and (3) evidence that the intervention tools are accessed
and used by prescribing members of staff at intervention
trial arm practices. Components of the trial that are
deemed to be unacceptable or unfeasible will be modi-
ﬁed. The remaining practices will be allocated once
there is evidence that the interventions are being suc-
cessfully delivered and used by practices.
Study setting and target population
The study will be conducted in the CPRD. The CPRD is
the largest primary care database of longitudinal
medical records worldwide and includes about 7%
(coverage of over 11.3 million patients) of the UK
general practices.22 The CPRD data are generated via
GP computer systems, and special software collects data
from practice servers on a monthly basis. The CPRD
collect anonymised data on clinical diagnosis, labora-
tory tests, issued prescriptions, clinical referrals and hos-
pital admissions. To record healthcare, GPs can use a
combination of coded and free-text data.22 The regis-
tered population is generally representative of the UK
general population in terms of sex, age and ethnicity,
and the quality of EHRs data in the CPRD are well
described.23 General practices in England, Scotland,
Wales and Northern Ireland that presently contribute
research quality data to the CPRD will be eligible for
the study.
General practices which contribute data to CPRD will
be invited to participate by CPRD and will be asked to
provide written consent. Only those practices that use
DXS-Point-Of-Care software, Vision system software and
which are located in areas that have given research gov-
ernance approval for the study will be eligible to partici-
pate. The target population for this trial is the general
population registered with general practices in the UK,
including England, Scotland, Wales and Northern
Ireland. The immediate participants in the research are
health professionals who may issue prescriptions for anti-
biotics at the UK general practices.24 Outcomes will be
evaluated using the anonymised EHRs for individual
patients registered with the UK general practices who
may consult with RTIs and receive antibiotic
prescriptions.
Ethical approval
CPRD general practices that give informed consent to
the study will be included in the trial. The intervention
is at general practice level; therefore, individual patient
consent will not be sought.
Sample size calculations
Stata V.13 was used for calculations. In order to obtain a
result as precise as possible, we aimed to achieve the
maximum feasible sample size. At the trial start in
January 2015, there were 427 general practices active in
CPRD. Based on previous experience,18 we estimated
that it would be feasible to recruit a maximum of 120
CPRD general practices. The mean practice list size was
8537, and 120 general practices will include some 1.20
million registered patients, with about 224 000 RTI con-
sultations over 12 months. Power calculations were com-
puted based on primary outcome of antibiotic
prescribing for RTI per 1000 participant-years, using
data from the previous eCRT study.18 In the eCRT study,
which included participants aged 18–59 years, the mean
antibiotic prescribing rate for RTI was 112 per 1000 (SD
39.8). Therefore, for this study, based on the analysis of
covariance, where participants of all ages will be
included, including 60 GP practices in each trial arm,
there will be more than 80% power, with two-sided
α=0.05, to detect an absolute reduction in antibiotic pre-
scription for RTI of 12 per 1000 registered patient years
(or 1.2 per 100). If the SD is 25% larger, the study will
still have 80% power to detect a reduction in antibiotic
prescribing of 15 per 1000 (1.5 per 100 patients), or
17.5 per 1000 if the SD is 50% larger.
Allocation
The allocation will be performed at King’s College
London using anonymised practice identiﬁers passed
from CPRD. The research team are at all times blind to
the identity of trial practices, which is only known to
CPRD staff. GP practices are allocated to intervention
and control trial arms by minimisation controlling for
baseline antibiotic prescribing quartile region (England,
Scotland, Wales and Northern Ireland). Anonymised
practice identiﬁers will then be returned to CPRD with
trial arm allocation attached. This information will then
be used to enable intervention activation at practices in
the intervention trial arms. This procedure is considered
to ensure adequate concealment throughout the alloca-
tion process.
Juszczyk D, et al. BMJ Open 2016;6:e010892. doi:10.1136/bmjopen-2015-010892 3
Open Access
Intervention development and implementation
The development of the intervention was informed by
existing health records, behaviour change theory, system-
atic review evidence, clinical guidelines, qualitative
research with non-trial practices (31 GPs and 3 nurse
prescribers interviewed), as well as process evaluation
data from the previous proof-of-concept trial.25 Main ele-
ments used in the previous eCRT study were reﬁned and
new elements were added. Two novel major components
are the provision of practice-level feedback on antibiotic
prescribing and recruitment of a GP champion for each
practice since facilitation plays an important role affect-
ing the context in which change occurs.26 A large part
of the intervention reﬁnement focused on the investiga-
tion of factors inﬂuencing implementation and selection
of modiﬁcations of the tools in order to achieve
maximum beneﬁts of the intervention.
Practices in the intervention arm will receive complex
multicomponent interventions, delivered remotely,
which will include a 6 min web-based training webinar to
promote effective usage of the intervention materials;
prescribing support tools which will appear on interven-
tion family practitioners’ screens during consultations
for speciﬁc RTI; monthly feedback on practice antibiotic
prescribing in the preceding month from EHR analysis.
Control practices will continue with usual care. The
intervention will continue for 12 months. A detailed
description of the development and design of the elec-
tronic prompts has been reported elsewhere27 and will
be updated for this study.
In order to preserve practices’ anonymity, general
practice recruitment will be conducted through the
ofﬁces of CPRD. To ensure that an adequate practice
recruitment and enrolment is achieved, regular meet-
ings will be held with CPRD and Trial Steering
Committee (TSC) overlooking the recruitment process.
All CPRD general practices that are located in areas
where research governance approvals have been
obtained will receive an invitation pack, including a
letter, consent form and information sheet. CPRD
general practices that give informed consent to the study
will be included in the trial. Intervention tools will be
installed onto family practice information systems
remotely as an add-on to existing software (DXS-
Point-Of-Care). At the beginning of the intervention,
GPs and nurse prescribers at intervention practices will
be encouraged to watch a 6 min video narrated by a
practising GP which aims to present the study and
promote its effective usage. Once the tools become avail-
able on the practice system, a pop-up banner would
appear after the ﬁrst log-in to inform the doctor/nurse
that the study tools are available on their system. During
consultations for RTIs, electronic prompts will be acti-
vated by the entry of speciﬁc Read codes related to RTIs.
Healthcare professionals will see the prompts in the
right bottom corner of their screen and these prompts
would offer two options to select: an option to print out
a patient information leaﬂet or an option to check
whether a patient is among a group of patients who are
likely to be at risk of developing complications. Five
condition-speciﬁc leaﬂets are available for adults (for
common cold, sore throat, cough and bronchitis, sinus-
itis and otitis media). There are also two separate leaﬂets
for parents of children who present with cough or
middle ear infection. The leaﬂets give patients informa-
tion on realistic recovery times, self-management strat-
egies, explain why antibiotics are not needed, inform
about the modest beneﬁts and potential harms from
antibiotic treatment, list serious signs of when patients
should seek medical help and provide patients with
clear guidelines as to when they should reconsult if their
symptoms do not improve. These prompts aim to help
GPs follow the guideline behaviour. The main focus is to
encourage GPs not to prescribe antibiotics rather than
to prescribe an antibiotic or offer a delayed prescription.
All management decisions for individual patients remain
at the discretion of individual GPs. Each practice in the
intervention arm will also receive monthly feedback on
their antibiotic prescribing in the preceding month
from CPRD analysis. The reports would present the pre-
scribing rates in a table format and would also include
evidence for safe best practice in RTIs management.
Practices will be encouraged to review the monthly feed-
back received as part of the trial during practice meet-
ings. GP champion for each practice will be encouraged
to circulate the feedback prior to the meeting and
ensure that the discussion of the feedback is on the
meeting agenda.
Outcome evaluation
The effectiveness of the intervention will be evaluated
by analysing EHRs that are routinely collected into the
CPRD database during a deﬁned study period and his-
torical information will be used to assess preintervention
data. Data available for each participant will comprise
their entire anonymised electronic medical record,
including medical (Read) codes associated with consul-
tations and referrals, and details of all drugs pre-
scribed.22 CPRD data are also linked to Hospital Episode
Statistics (HES) data for consenting practices in
England. The primary outcome will be the number of
antibiotic prescriptions for RTI per 1000 patient years.
Secondary outcomes will be: the RTI consultation rate;
the proportion of consultations for RTI with an anti-
biotic prescribed; subgroups of age; different categories
of respiratory infections, including colds, sore throat,
cough and bronchitis, otitis media and rhinosinusitis;
and quartiles of intervention usage.
Analyses will be implemented according to the
‘intention-to-treat’ principle, including in the analysis all
eligible person-time for all allocated practices, including
data for any practices that later withdraw from CPRD or
participants who subsequently ended their registration
during the study period. Individual patient data will be
included for participants who are currently registered
with participating CPRD practices (no patient exclusion
4 Juszczyk D, et al. BMJ Open 2016;6:e010892. doi:10.1136/bmjopen-2015-010892
Open Access
criteria). Preintervention data on antibiotic prescribing
for the 12 months preceding the intervention will be
analysed as baseline.
Trial analyses will be implemented using data aggre-
gated to general practice level, using the family practice-
speciﬁc rates or proportions as observations. This is the
level for intended inferences. Effects of clinical and
public health importance will be evident at this level. In
general, a perfectly weighted cluster-level analysis will
give similar precision as an individual-level analysis.28
Analyses for primary and secondary outcomes will esti-
mate the difference (95% CI) in the outcome between
intervention and control trial arms. Primary and second-
ary analyses will be adjusted for the preintervention
value of the outcome, in an analysis of covariance frame-
work, as well as proportion by age group and proportion
of women at the practice. Minimum variance weights
will be used to allow for varying numbers of participants
and consultations per practice.29 Intervention usage
(number of times prescribing reports or decision
support tools are accessed) will be divided into quartiles
and a trend tests implemented by introducing these into
analyses as continuous variables. Data for healthcare
usage and costs will be analysed at the individual level
using a two-part model as reported previously.30 Given
the extent of data available for analysis, we can readily
evaluate shifts in practices’ use of diagnostic categories,
using pretrial data to evaluate time trends.
Process evaluation
A process evaluation will be conducted to evaluate the
barriers and facilitators to implementation and the use
of the intervention using a mixed-methods approach.
Participants in the process evaluation will primarily
include GPs, but staff involved with intervention imple-
mentation will also be included, aiming pragmatically
for the maximum achievable sample. We will aim to
recruit practitioners with a range of experiences of the
intervention to explore their unique and important per-
spective. A questionnaire and an interview guide will be
developed guided by criteria suggested by Linnan and
Steckler31 for the process evaluation of public health
interventions and research and will explore participants’
experiences of using the intervention materials and
experiences of the study implementation. Inductive the-
matic analysis will be used to analyse qualitative data. As
a part of process evaluation, contextual information on
initiatives to inﬂuence antibiotic prescribing, which
might be implemented both locally and nationally, will
be collected. This will include periodic surveys of docu-
mentary sources, primarily those accessible on the inter-
net. It will also include speciﬁc questionnaire items
concerning participating practices’ exposure to other
inﬂuences, such as interaction with the local National
Health Service (NHS) prescribing advisers. As a part of
process evaluation, compliance with the intervention
protocol will be assessed. This will be done by evaluating
the total number of times the intervention tools
(including the practice prescribing reports, the decision
support tools and webinars) are accessed over the inter-
vention period.
Participant safety
Safety outcomes would include diagnoses of pneumonia,
empyema, peritonsillar abscess, mastoiditis, intracranial
abscess, meningitis, osteomyelitis, pyelonephritis, Scarlet
fever, septic arthritis, septicaemia/toxic shock and mor-
tality. The incidence of these will be compared between
trial arms and across high and low antibiotic prescribing
practices divided into quartiles.
Adverse events/reactions
All management decisions for individual patients remain
at the discretion of individual GPs. Therefore, we do not
anticipate any potential serious adverse events that could
be directly attributable to the intervention. However, we
will ask GPs at participating general practices to notify
the study team of any possible adverse events. If any
such reports are received the TSC and the Research
Ethics Committee will be notiﬁed.
Independent monitoring and quality control
TSC including a Data Monitoring Committee (DMC)
have been set up to monitor the conduct of the trial
and will meet throughout the study duration. The TSC
will include among others a member of the patient par-
ticipation group and an independent GP member.
Economic evaluation plan
Total healthcare usage costs will be estimated from
CPRD data, using methods reported previously,18 and
compared between trial arms. Analyses will evaluate
primary care usage including consultations at the prac-
tice, emergency consultations, home visits, out-of-hours
visits and telephone consultations; hospital usage
included inpatient admissions, outpatient episodes, day
cases and emergency episodes. A standard two-stage
approach will be used to estimate costs. A probit model
will be used to estimate the probability of any healthcare
being used, because some patients will not use health-
care during the period of study. A general linear model
will then be used to estimate the mean costs for partici-
pants who make any use of healthcare. The costs of
healthcare will be multiplied by the probability of using
healthcare to obtain the ﬁnal estimate, which will be
compared between trial arms.
Reporting and dissemination
A number of publications in peer-reviewed journals are
expected from this trial and these will include descrip-
tion of the intervention development and intervention
content; main ﬁndings of the trial; ﬁndings of a mixed-
methods evaluation of trial procedures. All these publi-
cations will be made available in open access journals in
order to provide access to all readers anywhere in the
world.
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Protocol amendments
Protocol amendments will be communicated to the
Study Management Group, the TSC, the DMC, the
funder (National Institute for Health Research (NIHR)
Health Technology Assessment programme) and to the
Research Ethics Committee.
Study status
The intervention development phase has been com-
pleted. Recruitment for the trail started in August 2015.
The ﬁrst batch of 19 practices was randomised in
November 2015 and these practices acted as an internal
pilot. Currently, 76 practices are part of the study.
DISCUSSION
This intervention will use EHRs as a means to inform,
deliver and evaluate the effectiveness of a cluster trial to
support antibiotic prescribing. The 60 trial practices
which will be randomised to the intervention arm of this
trial may include more than 600 000 individual partici-
pants, allowing detection of small effects that could be
widely implemented and be of public health importance.
Careful planning of this intervention could help to over-
come some of the challenges associated with deploying
effective intervention components into routine practice
setting. In addition, this trial will provide evidence on
more effective roll-out of strategies at changing prescri-
bers’ behaviour into routine practice settings without
resource-intensive interventions. A step-wedge design
might be considered in evaluating the future roll-out of
apparently successful interventions.32 A key output from
this research will be establishing a way of delivering a mul-
ticomponent intervention through electronic media in
order to change antibiotic prescribing behaviour in
primary care. Importantly, rigorous process evaluation
conducted as a part of this study will examine facilitators,
barriers and obstacles to implementation of this interven-
tion and assess compliance with the intervention proto-
col. This will help to establish whether the behaviour of
health professionals was modiﬁed as a result of being
part of the study or being exposed to the intervention
tools. If effective, the intervention could be easily trans-
lated into routine practice settings at very low cost.
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